Marker Therapeutics, Inc. (MRKR) — DEF 14A Filings
All DEF 14A filings from Marker Therapeutics, Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
Marker Therapeutics Proxy Statement Filed for June 6 Meeting
— Apr 24, 2025 Risk: medium
Marker Therapeutics, Inc. filed its definitive proxy statement on April 24, 2025, for its annual meeting on June 6, 2025. The company, formerly known as TAPIMMU -
Marker Therapeutics Files Definitive Proxy Statement
— Feb 4, 2025 Risk: low
Marker Therapeutics, Inc. filed its definitive proxy statement on February 4, 2025, for its annual meeting. The filing concerns the solicitation of proxies for -
Marker Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders
— Apr 26, 2024 Risk:
Marker Therapeutics, Inc. (MRKR) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Annual Meeting of Stockholders to be held virtually on June 6
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX